You are here

ASCO 2021

Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy

Endpoints

Thu, 11/11/21 - 11:37 pm

TCR therapeutics

Digital tools key to immuno-oncology’s future: report

Pharmaforum

Sun, 07/25/21 - 11:49 am

immuno-oncology

ASCO 2021 movers – PDS wins, but big pharma reigns

EP Vantage

Wed, 06/9/21 - 11:00 am

PDS Biotechnology

Spectrum Pharma

Black Diamond Therapeutics

Alpine Immune Sciences

Harpoon Therapeutics

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

BioSpace

Mon, 06/7/21 - 08:41 pm

With Illumina Acquisition Pending, GRAIL Presents Multi-Cancer Detection Test

BioSpace

Mon, 06/7/21 - 08:32 pm

clinical trials

ASCO 2021 – the exon 20 army lines up behind Rybrevant

EP Vantage

Mon, 06/7/21 - 11:12 am

exon 20-insertion NSCLC

Dizal Pharmaceutical

Black Diamond Therapeutics

ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

Pharmaforum

Mon, 06/7/21 - 11:07 am

Gilead Sciences

Bayer at ASCO: Vitrakvi Effective in TRK Fusion Cancers Regardless of Tumor Type

BioSpace

Sun, 06/6/21 - 10:31 pm

#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval

Endpoints

Sat, 06/5/21 - 02:25 pm

Gilead Sciences

ASCO Update: A Theme of Accessibility and Pricing Plus Individual Reporting

BioSpace

Sat, 06/5/21 - 02:23 pm

#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC

Endpoints

Sat, 06/5/21 - 02:17 pm

clinical trials

#ASCO21: Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients

Endpoints

Fri, 06/4/21 - 11:00 am

Gilead Sciences

triple negative breast cancer

#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'

Endpoints

Fri, 06/4/21 - 10:48 am

non-small cell lung cancer

ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus

EP Vantage

Fri, 06/4/21 - 10:41 am

nemvaleukin alfa

Novartis Breaks Through with Radioligand Therapy for Prostate Cancer

BioSpace

Fri, 06/4/21 - 10:36 am

prostate cancer

An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?

BioPharma Dive

Thu, 06/3/21 - 11:11 pm

genetic breast cancer

Sanofi ASCO Preview: Addressing Unmet Needs in Breast Cancer

BioSpace

Thu, 06/3/21 - 11:08 pm

clinical trials

ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer

Fierce Pharma

Thu, 06/3/21 - 11:05 pm

#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle

Endpoints

Thu, 06/3/21 - 10:51 am

follicular lymphoma

Gilead Sciences

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance

Endpoints

Thu, 06/3/21 - 12:09 am

Pages